Report in English with a Dutch summary (KCE reports 45A)
Report in English with a Dutch summary (KCE reports 45A) Report in English with a Dutch summary (KCE reports 45A)
48 Screening for Colorectal Cancer KCE reports vol.45 4 GUIDELINES ON COLORECTAL CANCER SCREENING AND SURVEILLANCE 4.1 INTRODUCTION A quick explorative Medline search, focusing on colorectal cancer combined with either screening or surveillance and with addition of the search term guideline$ for the field publication type yielded 45, respectively 24 citations if restricted to the years 2000 2006. Subsequently we searched additional guidelines sources (see appendix for details). We retrieved guidelines on average risk screening as well as on surveillance and management of groups at increased risk of colorectal cancer, however limited to the years 2000 - 2006. Older or rescinded guidelines, as well as guidelines and recommendations in other languages than English, Dutch or French were disregarded. Excluded were also guidelines exclusively restricted to treatment of CRC or genetic testing for hereditary colorectal cancer. As a result of those searches, 20 full-text guidelines & recommendations were obtained, including, for some of them, their NGC appraisals. 4.2 GENERAL PRINCIPLES Clinical practice guidelines (CPG) are defined as systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances (Oxford Centre for Evidence-Based Medicine - CEBM169, 170). 1. Good CPG provide graded recommendations about a specific health problem, based on the best evidence available at the time they are derived by means of a systematic review of the scientific literature and representing consensus opinion of experts gathered 171 through Consensus development conferences, Expert Consensus Committees, Delphi method, Nominal Group Technique, etc. The former (the systematic review) implies the application of rating schemes for appraisal of the strength of reviewed evidence 172, 173, the latter (the consensus opinion) a shared framework for their development, reporting and assessment 174. Ideally, each guideline consists of an algorithm or decision pathway outlining diagnostic, therapeutic and supportive care management, a manuscript discussing important issues related to the algorithm, and references providing data on which the recommendations are based 58. Furthermore, a good guideline should consider all relevant disciplines and stakeholders, as well as the local circumstances in which healthcare is delivered 175. It is however essential that these recommendations are continuously updated and revised to reflect new data and new clinical information. 2. To ensure that clinical guidelines improve patient care they should meet minimum quality criteria 176, 177. In the mid nineties a group of researchers from 13 countries developed the Appraisal of Guidelines Research and Evaluation (AGREE) Instrument. The objectives of the project were to provide a framework to create
KCE reports vol.45 Screening for Colorectal Cancer 49 a coordinated international approach to the appraisal of clinical guidelines and to identify potential areas for harmonization of guideline development178, 174. Health Care/Prevention Recommendations (HC/PR), on the other hand, are issued by regional, national or supranational (EU, WHO, ) governmental advisory committees involved with public health and chiefly address the public, politicians and the public health administrations of the respective countries. They focus on implementation of cancer screening programs within the frame of the general priority setting on the use of healthcare resources, screening coverage and compliance, quality assurance at all levels and good public information about benefits and risks 179. Although grounded on published scientific evidence, structured grading of the evidence generally is not their main concern. Table 11 gives an overview of the 20 retrieved guidelines and recommendations on CRC screening and surveillance. Some of them solely deal with average risk screening (mass screening), others include recommendations on increased risk screening and/or surveillance topics.
- Page 7 and 8: KCE reports vol.45A Colorectale Kan
- Page 9: KCE reports vol.45A Colorectale Kan
- Page 12 and 13: 2 Screening for Colorectal Cancer K
- Page 14 and 15: 4 Screening for Colorectal Cancer K
- Page 16 and 17: 6 Screening for Colorectal Cancer K
- Page 18 and 19: 8 Screening for Colorectal Cancer K
- Page 20 and 21: 10 Screening for Colorectal Cancer
- Page 22 and 23: 12 Screening for Colorectal Cancer
- Page 24 and 25: 14 Screening for Colorectal Cancer
- Page 26 and 27: 16 Screening for Colorectal Cancer
- Page 28 and 29: 18 Screening for Colorectal Cancer
- Page 30 and 31: 20 Screening for Colorectal Cancer
- Page 32 and 33: 22 Screening for Colorectal Cancer
- Page 34 and 35: 24 Screening for Colorectal Cancer
- Page 36 and 37: 26 Screening for Colorectal Cancer
- Page 38 and 39: 28 Screening for Colorectal Cancer
- Page 40 and 41: 30 Screening for Colorectal Cancer
- Page 42 and 43: 32 Screening for Colorectal Cancer
- Page 44 and 45: 34 Screening for Colorectal Cancer
- Page 46 and 47: 36 Screening for Colorectal Cancer
- Page 48 and 49: 38 Screening for Colorectal Cancer
- Page 50 and 51: 40 Screening for Colorectal Cancer
- Page 52 and 53: 42 Screening for Colorectal Cancer
- Page 54 and 55: 44 Screening for Colorectal Cancer
- Page 56 and 57: 46 Screening for Colorectal Cancer
- Page 60 and 61: 50 Screening for Colorectal Cancer
- Page 62 and 63: 52 Screening for Colorectal Cancer
- Page 64 and 65: 54 Screening for Colorectal Cancer
- Page 66 and 67: 56 Screening for Colorectal Cancer
- Page 68 and 69: 58 Screening for Colorectal Cancer
- Page 70 and 71: 60 Screening for Colorectal Cancer
- Page 72 and 73: 62 Screening for Colorectal Cancer
- Page 74 and 75: 64 Screening for Colorectal Cancer
- Page 76 and 77: 66 Screening for Colorectal Cancer
- Page 78 and 79: 68 Screening for Colorectal Cancer
- Page 80 and 81: 70 Screening for Colorectal Cancer
- Page 82 and 83: 72 Screening for Colorectal Cancer
- Page 84 and 85: 74 Screening for Colorectal Cancer
- Page 86 and 87: 76 Screening for Colorectal Cancer
- Page 88 and 89: 78 Screening for Colorectal Cancer
- Page 90 and 91: 80 Screening for Colorectal Cancer
- Page 92 and 93: 82 Screening for Colorectal Cancer
- Page 94 and 95: 84 Screening for Colorectal Cancer
- Page 96 and 97: 86 Screening for Colorectal Cancer
- Page 98 and 99: 88 Screening for Colorectal Cancer
- Page 100 and 101: 90 Screening for Colorectal Cancer
- Page 102 and 103: 92 Screening for Colorectal Cancer
- Page 104 and 105: 94 Screening for Colorectal Cancer
- Page 106 and 107: 96 Screening for Colorectal Cancer
<strong>KCE</strong> <strong>reports</strong> vol.45 Screen<strong>in</strong>g for Colorectal Cancer 49<br />
a coord<strong>in</strong>ated <strong>in</strong>ternational approach to the appraisal of cl<strong>in</strong>ical<br />
guidel<strong>in</strong>es and to identify potential areas for harmonization of<br />
guidel<strong>in</strong>e development178, 174.<br />
Health Care/Prevention Recommendations (HC/PR), on the other hand, are<br />
issued by regional, national or supranational (EU, WHO, ) governmental<br />
advisory committees <strong>in</strong>volved <strong>with</strong> public health and chiefly address the public,<br />
politicians and the public health adm<strong>in</strong>istrations of the respective countries.<br />
They focus on implementation of cancer screen<strong>in</strong>g programs <strong>with</strong><strong>in</strong> the frame<br />
of the general priority sett<strong>in</strong>g on the use of healthcare resources, screen<strong>in</strong>g<br />
coverage and compliance, quality assurance at all levels and good public<br />
<strong>in</strong>formation about benefits and risks 179. Although grounded on published<br />
scientific evidence, structured grad<strong>in</strong>g of the evidence generally is not their ma<strong>in</strong><br />
concern.<br />
Table 11 gives an overview of the 20 retrieved guidel<strong>in</strong>es and recommendations<br />
on CRC screen<strong>in</strong>g and surveillance. Some of them solely deal <strong>with</strong> average risk<br />
screen<strong>in</strong>g (mass screen<strong>in</strong>g), others <strong>in</strong>clude recommendations on <strong>in</strong>creased risk<br />
screen<strong>in</strong>g and/or surveillance topics.